DE60127143D1 - Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung - Google Patents
Bispezifische Antikörper gegen CD19 und CD16 und deren VerwendungInfo
- Publication number
- DE60127143D1 DE60127143D1 DE60127143T DE60127143T DE60127143D1 DE 60127143 D1 DE60127143 D1 DE 60127143D1 DE 60127143 T DE60127143 T DE 60127143T DE 60127143 T DE60127143 T DE 60127143T DE 60127143 D1 DE60127143 D1 DE 60127143D1
- Authority
- DE
- Germany
- Prior art keywords
- antibodies
- polynucleotides
- vectors
- human
- antibodies against
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01127061A EP1314741B1 (de) | 2001-11-14 | 2001-11-14 | Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60127143D1 true DE60127143D1 (de) | 2007-04-19 |
DE60127143T2 DE60127143T2 (de) | 2007-11-15 |
Family
ID=8179236
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60127143T Expired - Lifetime DE60127143T2 (de) | 2001-11-14 | 2001-11-14 | Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung |
Country Status (8)
Country | Link |
---|---|
US (1) | US20050089519A1 (de) |
EP (1) | EP1314741B1 (de) |
JP (1) | JP4373788B2 (de) |
AT (1) | ATE356149T1 (de) |
AU (1) | AU2002356601A1 (de) |
DE (1) | DE60127143T2 (de) |
ES (1) | ES2283368T3 (de) |
WO (1) | WO2003048209A1 (de) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
EP1354600A1 (de) * | 2002-04-19 | 2003-10-22 | Affimed Therapeutics AG | Antikörperkombination verwendbar für Tumortherapie |
GB0510790D0 (en) | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
EP1912675B1 (de) | 2005-07-25 | 2014-02-12 | Emergent Product Development Seattle, LLC | B-zell-verringerung mit cd37-spezifischen und cd20-spezifischen bindungsmolekülen |
US8409577B2 (en) | 2006-06-12 | 2013-04-02 | Emergent Product Development Seattle, Llc | Single chain multivalent binding proteins with effector function |
AU2007285976B2 (en) | 2006-08-14 | 2011-08-18 | Xencor, Inc | Optimized antibodies that target CD19 |
CA2662340C (en) * | 2006-09-08 | 2016-08-02 | Medimmune, Llc | Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
DE502006009060D1 (de) * | 2006-09-22 | 2011-04-21 | Wacker Chemie Ag | Verfahren zur fermentativen Herstellung von Antikörpern |
EP2014680A1 (de) * | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Rekombinante, einkettige, trivalente trispezifische oder bispezifische Antikörperderivate |
DE102007041834A1 (de) * | 2007-09-03 | 2009-03-05 | Siemens Ag | Arzneimittel zur Behandlung eines Karzinoms |
JP6013733B2 (ja) | 2008-04-11 | 2016-10-25 | エマージェント プロダクト デベロップメント シアトル, エルエルシー | Cd37免疫治療薬および二機能性化学療法薬とのその組合せ |
WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
WO2012066058A1 (en) | 2010-11-16 | 2012-05-24 | Boehringer Ingelheim International Gmbh | Agents and methods for treating diseases that correlate with bcma expression |
US8969318B2 (en) * | 2010-12-10 | 2015-03-03 | Merck Patent Gmbh | Bispecific aptamers mediating tumour cell lysis |
US20140155581A1 (en) * | 2011-07-06 | 2014-06-05 | Medimmune, Llc | Methods For Making Multimeric Polypeptides |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
EP2762496A1 (de) | 2013-02-05 | 2014-08-06 | EngMab AG | Verfahren zur Auswahl von Antikörpern gegen BCMA |
WO2014122144A1 (en) | 2013-02-05 | 2014-08-14 | Engmab Ag | BISPECIFIC ANTIBODIES AGAINST CD3ε AND BCMA |
EP2789630A1 (de) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispezifische Antikörper gegen CD3e und ROR1 |
CA2963692A1 (en) | 2014-10-09 | 2016-04-14 | Engmab Ag | Bispecific antibodies against cd3epsilon and ror1 |
US11000603B2 (en) | 2015-04-14 | 2021-05-11 | Benhealth Biopharmaceutic (Shenzhen) Co., Ltd. | Multi-specific binding conjugate, related pharmaceutical compositions and use |
RS60030B1 (sr) | 2015-08-03 | 2020-04-30 | Engmab Sarl | Monoklonska antitela protiv humanog antigena sazrevanja b ćelija (bcma) |
MA44909A (fr) | 2015-09-15 | 2018-07-25 | Acerta Pharma Bv | Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk |
KR20180053322A (ko) | 2015-09-21 | 2018-05-21 | 압테보 리서치 앤드 디벨롭먼트 엘엘씨 | Cd3 결합 폴리펩타이드 |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
AU2016330807B2 (en) * | 2015-10-02 | 2023-08-10 | F. Hoffmann-La Roche Ag | Anti-human CD19 antibodies with high affinity |
US11525009B2 (en) | 2016-06-22 | 2022-12-13 | Benhealth Biopharmaceutic (Shenzhen) Co. Ltd. | Bispecific antibody and antibody conjugate for tumor therapy and use thereof |
CN110167964B (zh) | 2016-11-02 | 2023-12-01 | 百时美施贵宝公司 | 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物 |
CA3051062C (en) * | 2017-02-28 | 2023-09-26 | Affimed Gmbh | Tandem diabody for cd16a-directed nk-cell engagement |
AU2018385409A1 (en) * | 2017-12-12 | 2020-07-02 | Macrogenics Inc. | Bispecific CD 16-binding molecules and their use in the treatment of disease |
EP3806888B1 (de) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Von pde5 abgeleitete regulatorische konstrukte und verfahren zur verwendung in der immuntherapie |
WO2020089437A1 (en) | 2018-10-31 | 2020-05-07 | Engmab Sàrl | Combination therapy |
CN113508127A (zh) | 2018-11-06 | 2021-10-15 | 阿尔萨泰克公司 | 神经变性疾病的基于细胞的基因疗法 |
CN113272327A (zh) | 2018-12-30 | 2021-08-17 | 豪夫迈·罗氏有限公司 | 抗兔cd19抗体及其使用方法 |
RU2738802C1 (ru) * | 2019-08-21 | 2020-12-17 | Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" | Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула |
CN116745324A (zh) | 2021-01-27 | 2023-09-12 | 信达生物制药(苏州)有限公司 | 针对cd16a的单域抗体及其用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5843708A (en) * | 1988-01-05 | 1998-12-01 | Ciba-Geigy Corporation | Chimeric antibodies |
US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
ATE199392T1 (de) * | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
HUP9900956A2 (hu) * | 1998-04-09 | 2002-04-29 | Aventis Pharma Deutschland Gmbh. | Egyláncú, több antigéntkötőhely kialakítására képes molekulák, előállításuk és alkalmazásuk |
DE19819846B4 (de) * | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
-
2001
- 2001-11-14 AT AT01127061T patent/ATE356149T1/de active
- 2001-11-14 DE DE60127143T patent/DE60127143T2/de not_active Expired - Lifetime
- 2001-11-14 EP EP01127061A patent/EP1314741B1/de not_active Expired - Lifetime
- 2001-11-14 ES ES01127061T patent/ES2283368T3/es not_active Expired - Lifetime
-
2002
- 2002-11-14 JP JP2003549396A patent/JP4373788B2/ja not_active Expired - Fee Related
- 2002-11-14 WO PCT/EP2002/012776 patent/WO2003048209A1/en active Application Filing
- 2002-11-14 US US10/495,508 patent/US20050089519A1/en not_active Abandoned
- 2002-11-14 AU AU2002356601A patent/AU2002356601A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2003048209A1 (en) | 2003-06-12 |
ATE356149T1 (de) | 2007-03-15 |
AU2002356601A1 (en) | 2003-06-17 |
JP4373788B2 (ja) | 2009-11-25 |
JP2005517392A (ja) | 2005-06-16 |
US20050089519A1 (en) | 2005-04-28 |
ES2283368T3 (es) | 2007-11-01 |
EP1314741B1 (de) | 2007-03-07 |
EP1314741A1 (de) | 2003-05-28 |
DE60127143T2 (de) | 2007-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60127143D1 (de) | Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung | |
BR0209989A (pt) | Plataformas baseadas em cromossomas | |
NO20005296D0 (no) | CD19xCD3-spesifikke polypeptider og anvendelser derav | |
WO2003048334A3 (en) | Immunocytokines with modulated selectivity | |
WO2005097185A3 (en) | Irta-5 antibodies and their uses | |
ATE517125T1 (de) | ANTIKÖRPER GEGEN ßDEATH RECEPTOR 4ß (DR4) UND DEREN VERWENDUNGEN | |
ATE429450T1 (de) | Chimärische dr4 antikörper und ihre verwendung | |
DE69031410D1 (de) | Monoklonale Antikörper gegen den humanen alpha/beta-T-Zellenrezeptor, ihre Herstellung und Verwendung | |
DE69905739D1 (de) | Naphthopyrane die in c5-c6 anneliert sind, ihre herstellung sowie sie enthaltende zubereitungen und (co)polymermatrizen | |
AU706584C (en) | Immunoglobulin variants | |
WO2006076691A8 (en) | Irta-2 antibodies and their uses | |
CY1113145T1 (el) | Μορια υποδοχεα θυμικης στρωματικης λεμφοποιητινης και χρησεις αυτων | |
ATE551363T1 (de) | Verwendung von antikörper gegen interleukin-4 rezeptor und deren zusammensetzungen | |
DK0980429T3 (da) | Human Toll-lignende receptorproteiner, beslægtede reagenser og fremgangsmåder | |
CY1110505T1 (el) | Ανθρωπινα αντισωματα dr4 και χρησεις αυτων | |
DE69520149D1 (de) | Tie-2 ligande, verfahren zu ihrer herstellung, und ihre anwendungen | |
ATE322288T1 (de) | Zusammensetzungen zur immunisierung sowie deren verwendung | |
DE69724428D1 (de) | Humanisierte antikörper die an das gleiche antigen wie antikörper nr-lu-13 binden und deren verwendung in "pretargeting" verfahren | |
ATE435872T1 (de) | Anti-interleukin-1 rezeptor antikörper und deren verwendung | |
BRPI0417215A (pt) | antagonistas de receptor muscarìnico de acetilcolina m3 | |
DE60038739D1 (de) | Somatostatin analoge, deren radiomarkierte derivate und deren verwendung | |
DE69504959D1 (de) | Humanisierte monoklonale antikörper gegen humanes interleukin - 4 | |
DE69221845D1 (de) | Monoklonale Antikörper gegen humanes IgE | |
EE05293B1 (et) | RG1 polpeptiidiga seonduv antikeha, seda h?lmav immunkonjugaat ja nende kasutamine | |
DE60331147D1 (de) | Sonnenschutzmittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |